LLY

1,055.75

+4.06%↑

JNJ

246.12

+2.16%↑

ABBV

228.52

+3.65%↑

NVS

162.08

+1.42%↑

MRK

120.6

+1.53%↑

LLY

1,055.75

+4.06%↑

JNJ

246.12

+2.16%↑

ABBV

228.52

+3.65%↑

NVS

162.08

+1.42%↑

MRK

120.6

+1.53%↑

LLY

1,055.75

+4.06%↑

JNJ

246.12

+2.16%↑

ABBV

228.52

+3.65%↑

NVS

162.08

+1.42%↑

MRK

120.6

+1.53%↑

LLY

1,055.75

+4.06%↑

JNJ

246.12

+2.16%↑

ABBV

228.52

+3.65%↑

NVS

162.08

+1.42%↑

MRK

120.6

+1.53%↑

LLY

1,055.75

+4.06%↑

JNJ

246.12

+2.16%↑

ABBV

228.52

+3.65%↑

NVS

162.08

+1.42%↑

MRK

120.6

+1.53%↑

Search

Quanterix Corp

Deschisă

SectorSănătate

5.78 -2.86

Rezumat

Modificarea prețului

24h

Curent

Minim

5.53

Maxim

5.96

Indicatori cheie

By Trading Economics

Venit

-3.5M

-34M

Vânzări

16M

40M

Marjă de profit

-83.479

Angajați

471

EBITDA

5.7M

-31M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+21.56% upside

Dividende

By Dow Jones

Următoarele câștiguri

16 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

50M

288M

Deschiderea anterioară

8.64

Închiderea anterioară

5.78

Sentimentul știrilor

By Acuity

50%

50%

149 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 feb. 2026, 23:47 UTC

Acțiuni populare

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 feb. 2026, 22:59 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Grab Holdings to Buy U.S.-Based Stash Financial

11 feb. 2026, 23:54 UTC

Câștiguri

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 feb. 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11 feb. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 feb. 2026, 23:49 UTC

Câștiguri

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 feb. 2026, 23:45 UTC

Câștiguri

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 feb. 2026, 23:42 UTC

Câștiguri

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 feb. 2026, 23:41 UTC

Câștiguri

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 feb. 2026, 23:40 UTC

Câștiguri

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 feb. 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 feb. 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 feb. 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 feb. 2026, 22:59 UTC

Câștiguri

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 feb. 2026, 22:59 UTC

Câștiguri

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 feb. 2026, 22:59 UTC

Câștiguri

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 feb. 2026, 22:58 UTC

Câștiguri

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 feb. 2026, 22:57 UTC

Câștiguri

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 feb. 2026, 22:54 UTC

Câștiguri

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 feb. 2026, 22:53 UTC

Câștiguri

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 feb. 2026, 22:47 UTC

Câștiguri

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb. 2026, 22:47 UTC

Câștiguri

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb. 2026, 22:23 UTC

Câștiguri

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 feb. 2026, 22:22 UTC

Câștiguri

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 feb. 2026, 22:22 UTC

Câștiguri

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 feb. 2026, 22:19 UTC

Câștiguri

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 feb. 2026, 22:18 UTC

Câștiguri

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 feb. 2026, 22:18 UTC

Câștiguri

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 feb. 2026, 22:18 UTC

Câștiguri

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 feb. 2026, 22:16 UTC

Câștiguri

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

21.56% sus

Prognoză pe 12 luni

Medie 7.5 USD  21.56%

Maxim 8 USD

Minim 7 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

0

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

149 / 352 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat